Lung Adenocarcinoma Clinical Trials

28 recruiting

Lung Adenocarcinoma Trials at a Glance

37 actively recruiting trials for lung adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Shanghai, Los Angeles, and Chicago. Lead sponsors running lung adenocarcinoma studies include Fudan University, Shanghai Pulmonary Hospital, Shanghai, China, and Jonsson Comprehensive Cancer Center.

Browse lung adenocarcinoma trials by phase

Treatments under study

About Lung Adenocarcinoma Clinical Trials

Looking for clinical trials for Lung Adenocarcinoma? There are currently 28 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma
Samsung Medical Center59 enrolled1 locationNCT05528458
Recruiting

Shared Decision Making in Patients With Lung Cancer

SurgeryLung Adenocarcinoma
Sichuan Cancer Hospital and Research Institute190 enrolled1 locationNCT05191485
Recruiting
Phase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting
Phase 1Phase 2

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Advanced Lung Adenocarcinoma
The University of Texas Health Science Center at San Antonio44 enrolled1 locationNCT06516887
Recruiting
Not Applicable

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China690 enrolled14 locationsNCT04937283
Recruiting

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Lung Adenocarcinoma
Oscar Gerardo Arrieta Rodríguez332 enrolled1 locationNCT06181812
Recruiting
Phase 3

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Brain MetastasesLung AdenocarcinomaWhole-Brain Radiotherapy+2 more
Sun Yat-sen University220 enrolled3 locationsNCT07481786
Recruiting
Phase 2

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Adenocarcinoma+1 more
Emory University50 enrolled3 locationsNCT06495125
Recruiting
Not Applicable

Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma

Lung AdenocarcinomaLepidic-Predominant Lung Adenocarcinoma
Fondazione del Piemonte per l'Oncologia30 enrolled1 locationNCT07479095
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

Lung AdenocarcinomaPleural EffusionBiomarkers
Fu Jen Catholic University100 enrolled1 locationNCT07012759
Recruiting
Not Applicable

Engagement of Veterans With Lung Cancer

Lung AdenocarcinomaLung Cancer (NSCLC)
Palo Alto Veterans Institute for Research194 enrolled1 locationNCT07219251
Recruiting
Phase 1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid TumorMesotheliomaRenal Cancer+3 more
Nuvectis Pharma, Inc.140 enrolled12 locationsNCT05873686
Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Not Applicable

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

Lung AdenocarcinomaBulky TumorsUnresectable Cancer
Karl Landsteiner University of Health Sciences10 enrolled1 locationNCT07423169
Recruiting
Not Applicable

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

Lung AdenocarcinomaCigarette SmokerCurrent Smoker+2 more
Ohio State University Comprehensive Cancer Center3,584 enrolled1 locationNCT03199651
Recruiting
Early Phase 1

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Lung CancerLung AdenocarcinomaStage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center48 enrolled1 locationNCT07235280
Recruiting
Phase 3

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

Lung AdenocarcinomaCryotherapy Effect
Institut Bergonié214 enrolled1 locationNCT04339218
Recruiting
Phase 3

FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma

Multiple Brain Metastases in Lung Adenocarcinoma
Sun Yat-Sen University Cancer Center258 enrolled1 locationNCT07058428
Recruiting
Phase 1Phase 2

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Lung Adenocarcinoma
Jonsson Comprehensive Cancer Center60 enrolled1 locationNCT05558904